171 related articles for article (PubMed ID: 38071953)
1. Higher TP53 somatic mutation prevalence from liquid biopsy analysis in ever smoker non-small-cell lung cancer patients.
Erdem HB; Alay MT; Özdemir Z; Çevik E; Ateş Ö; Karaçin C; Şahin İ; Doğan M; Bahsi T
Mutat Res; 2024; 828():111847. PubMed ID: 38071953
[TBL] [Abstract][Full Text] [Related]
2. Spectrum of germline mutations in smokers and non-smokers in Brazilian non-small-cell lung cancer (NSCLC) patients.
Couto PP; Bastos-Rodrigues L; Schayek H; Melo FM; Lisboa RGC; Miranda DM; Vilhena A; Bale AE; Friedman E; De Marco L
Carcinogenesis; 2017 Oct; 38(11):1112-1118. PubMed ID: 28968711
[TBL] [Abstract][Full Text] [Related]
3. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
4. Survival prediction model for non-small cell lung cancer based on somatic mutations.
Zhang W; Lin X; Li X; Wang M; Sun W; Han X; Sun D
J Gene Med; 2020 Sep; 22(9):e3206. PubMed ID: 32367667
[TBL] [Abstract][Full Text] [Related]
5. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
6. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.
An SJ; Chen ZH; Su J; Zhang XC; Zhong WZ; Yang JJ; Zhou Q; Yang XN; Huang L; Guan JL; Nie Q; Yan HH; Mok TS; Wu YL
PLoS One; 2012; 7(6):e40109. PubMed ID: 22768234
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
8. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
Li S; Li L; Zhu Y; Huang C; Qin Y; Liu H; Ren-Heidenreich L; Shi B; Ren H; Chu X; Kang J; Wang W; Xu J; Tang K; Yang H; Zheng Y; He J; Yu G; Liang N
Br J Cancer; 2014 May; 110(11):2812-20. PubMed ID: 24743704
[TBL] [Abstract][Full Text] [Related]
9. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
[TBL] [Abstract][Full Text] [Related]
10. Hot spot mutations in Finnish non-small cell lung cancers.
Mäki-Nevala S; Sarhadi VK; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuuttila A; Knuutila S
Lung Cancer; 2016 Sep; 99():102-10. PubMed ID: 27565922
[TBL] [Abstract][Full Text] [Related]
11. Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing.
Sun JM; Choi YL; Ji JH; Ahn JS; Kim KM; Han J; Ahn MJ; Park K
Ann Oncol; 2015 Jan; 26(1):161-166. PubMed ID: 25355724
[TBL] [Abstract][Full Text] [Related]
12. The genomic landscape of nonsmall cell lung carcinoma in never smokers.
Boeckx B; Shahi RB; Smeets D; De Brakeleer S; Decoster L; Van Brussel T; Galdermans D; Vercauter P; Decoster L; Alexander P; Berchem G; Ocak S; Vuylsteke P; Deschepper K; Lambrechts M; Cappoen N; Teugels E; Lambrechts D; De Greve J
Int J Cancer; 2020 Jun; 146(11):3207-3218. PubMed ID: 31745979
[TBL] [Abstract][Full Text] [Related]
13. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
[TBL] [Abstract][Full Text] [Related]
14. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
[TBL] [Abstract][Full Text] [Related]
15. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
[TBL] [Abstract][Full Text] [Related]
16. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer.
Toyooka S; Matsuo K; Shigematsu H; Kosaka T; Tokumo M; Yatabe Y; Ichihara S; Inukai M; Suehisa H; Soh J; Kiura K; Fong KM; Lee H; Wistuba II; Gazdar AF; Mitsudomi T; Date H
Clin Cancer Res; 2007 Oct; 13(19):5763-8. PubMed ID: 17908966
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic malaysian patient population.
Liam CK; Leow HR; How SH; Pang YK; Chua KT; Lim BK; Lai NL; Kuan YC; Pailoor J; Rajadurai P
Asian Pac J Cancer Prev; 2014; 15(1):321-6. PubMed ID: 24528049
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Fifty Hotspot Mutations of Lung Squamous Cell Carcinoma in Never-smokers.
Lee HY; Lee SH; Won JK; Lee DS; Kwon NJ; Choi SM; Lee J; Lee CH; Lee SM; Yim JJ; Yoo CG; Kim YW; Han SK; Park YS
J Korean Med Sci; 2017 Mar; 32(3):415-420. PubMed ID: 28145643
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.
Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J
Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519
[TBL] [Abstract][Full Text] [Related]
20. Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary.
Anna L; Holmila R; Kovács K; Gyorffy E; Gyori Z; Segesdi J; Minárovits J; Soltész I; Kostic S; Csekeo A; Husgafvel-Pursiainen K; Schoket B
Mutagenesis; 2009 Nov; 24(6):475-80. PubMed ID: 19643813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
